



## Editorial Comment: Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy

Michael S Leapman <sup>1</sup>, Cassandra L Thiel <sup>2</sup>, Ilyssa O Gordon <sup>3</sup>, Adam C Nolte <sup>4</sup>, Aaron Perecman <sup>5</sup>, Stacy Loeb <sup>6</sup>, Michael Overcash <sup>7</sup>, Jodi D Sherman <sup>8</sup>

*1 Department of Urology, Yale School of Medicine, New Haven, CT, USA; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA; <sup>2</sup> Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA; Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY, USA; Department of Pathology, Cleveland Clinic, Cleveland, OH, USA; <sup>3</sup> Cleveland Clinic Sustainability, Cleveland, OH, USA; <sup>4</sup> Mount Sinai Hospital, Miami, FL, USA; <sup>5</sup> The Lahey Clinic, Burlington, MA, USA; <sup>6</sup> Department of Urology, New York University Langone Health, New York, NY, USA; Departments of Urology and Population Health, New York University Langone Health, New York, NY, USA; Manhattan Veterans Affairs Medical Center, New York, NY, USA; <sup>7</sup> Environmental Genome Initiative, Raleigh, NC, USA; <sup>8</sup> Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA; Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA*

Eur Urol. 2023 Jan 10;S0302-2838(22)02857-3

DOI: 10.1016/j.eururo.2022.12.008 | ACCESS: 36635108

Lorenzo Storino Ramacciotti <sup>1</sup>, Masatomo Kaneko <sup>1,2</sup>, Michael Eppler <sup>1</sup>, Giovanni E. Cacciamani <sup>1,3</sup>, Andre Luis Abreu <sup>1,3</sup>

*<sup>1</sup> University of Southern California - USC, Institute of Urology, Center for Image-Guided Surgery, Focal Therapy and Artificial Intelligence for Prostate Cancer, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; <sup>2</sup> Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan; <sup>3</sup> Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA*

### COMMENT

The concept of sustainability in medical practice involves minimizing the negative impact of healthcare activities on the environment without compromising patient care (1). This includes reducing waste, energy consumption, and greenhouse gas (GHG) emissions. Leapman et al. should be congratulated for their study, as it contributes to understanding the importance of the carbon footprint of prostate magnetic resonance imaging (MRI) and biopsy - both critical components of prostate cancer diagnosis and treatment (2).

The study involved academic medical centers in the USA, outpatient urology clinics, and health care

facilities. It estimated the GHG emissions (CO<sub>2</sub> equivalents) and equivalents of coal and gasoline burned in five clinical scenarios: I) multiparametric MRI (mpMRI) of the prostate with targeted and systematic biopsies (baseline); II) mpMRI with targeted biopsy cores only; III) systematic biopsy without MRI; IV) mpMRI with systematic biopsy only; V) biparametric MRI (bpMRI) with targeted and systematic biopsies. The data on materials and energy consumption, patient and staff travel were analyzed for each component (Steps) of the procedure, as follows: 1) pre-biopsy mpMRI; 2) Transrectal ultrasound (TRUS) and prostate biopsy in the outpatient clinic; 3) Pathology laboratory.

The results showed that the carbon footprint for a single patient undergoing mpMRI, TRUS with targeted and systematic prostate biopsy was 80.7 kg CO<sub>2</sub>, equivalent to burning 34.4 liters of gasoline or 40.5 kg of coal. Conversely, a systematic 12-core biopsy without mpMRI generated 36.2 kg CO<sub>2</sub> equivalent and was the less ominous scenario for the environment. Using bpMRI instead of mpMRI with targeted and systematic biopsies resulted in a 10.7% reduction in GHG emissions. Energy consumption, which includes power and electricity usage, was identified as the leading contributor to GHG emissions, with staff travel being the second most significant contributor. Among the procedure Steps, the mpMRI had the greatest impact on the carbon footprint, and the mpMRI alone contributed 42.7 kg CO<sub>2</sub>e (54.3% of the baseline scenario). If MRI is performed as a triage strategy to select candidates for biopsy (avoid unnecessary biopsies) and limit sampling to MRI-targeted suspicious areas, the carbon emissions would be reduced by 1.4 million kg CO<sub>2</sub>e per 100,000 patients, equivalent to consuming 700,000 liters of gasoline. This would have a considerable environmental impact since it is estimated that the USA and Europe combined perform over 2 million prostate biopsies annually (3).

Although the study provides valuable insights into the carbon footprint of transrectal prostate biopsy, it has limitations. Indeed, it does not explore the potential differences in GHG emissions between transrectal and transperineal biopsy procedures and does not account for downstream infectious complications, hospitalizations, etc. (4). Additionally, it would be valuable to evaluate the potential advantages of performing a “One-Stop” and “RAPID” procedure that combines MRI and prostate biopsy on the same day (5, 6). This approach could significantly reduce patient and staff travel, resulting in substantial environmental benefits. Further improvements in MRI protocols, such as fast and bpMRI, and the integration of artificial intelligence (AI) algorithms could enhance MRI performance, address its limitations, and substantially decrease unnecessary prostate biopsies (7).

Overall, this study highlights the importance of sustainable solutions to reduce the carbon footprint in healthcare. An optimal pathway for sustainability associated with patient care would include: I) One-Stop bpMRI with fast protocols aided by AI; II) targeted biopsy exclusively; III) a transperineal approach performed under local anesthesia in an office-based setting. Further research is needed to establish sustainable solutions for reducing greenhouse gas emissions in prostate cancer management that do not compromise the individual yet minimize environmental impact while benefiting humankind.

## CONFLICT OF INTEREST

Andre Luis Abreu is consultant for Koelis and Quibim

## REFERENCES

1. Lenzen M, Malik A, Li M, Fry J, Weisz H, Pichler PP, et al. The environmental footprint of health care: a global assessment. *Lancet Planet Health*. 2020;4:e271-e279.
2. Leapman MS, Thiel CL, Gordon IO, Nolte AC, Perecman A, Loeb S, et al. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. *Eur Urol*. 2023:S0302-2838(22)02857-3. Epub ahead of print.
3. Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. *Eur Urol*. 2017;71:353-65.
4. Pradere B, Veeratterapillay R, Dimitropoulos K, Yuan Y, Omar MI, MacLennan S, et al. Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. *J Urol*. 2021;205:653-63.
5. Tafuri A, Ashrafi AN, Palmer S, Shakir A, Cacciamani GE, Iwata A, et al. One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis. *World J Urol*. 2020;38:949-56.
6. Eldred-Evans D, Connor MJ, Bertonecchi Tanaka M, Bass E, Reddy D, et al. The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway. *BJU Int*. 2023;131:461-70.
7. van der Leest M, Israël B, Cornel EB, Zámečník P, Schoots IG, van der Lelij H, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. *Eur Urol*. 2019;76:574-81.

### **Andre Abreu, MD**

Institute of Urology  
University of Southern California - USC  
1441 Eastlake Avenue, Suite 7416  
Los Angeles, California 90089-2211  
FAX: + 1 323 865-0120  
E-mail: andre.abreu@med.usc.edu

## ARTICLE INFO

 **Andre Abreu**  
<http://orcid.org/0000-0002-9167-2587>

**Int Braz J Urol. 2023; 49: 383-5**

Submitted for publication:  
March 25, 2023

Accepted after revision:  
April 05, 2023

Published as Ahead of Print:  
April 15, 2023